BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20223721)

  • 1. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
    Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
    Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
    Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
    Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
    Yağcı M; Karakaya F; Suyanı E; Haznedar R
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
    van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
    Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.
    Mohammed N; Chandran PA; Kandregula M; Mattaparthi RD; Gundeti S; Volturi J; Darapuneni R; Raju SB; Dattatreya PS
    Asian Pac J Cancer Prev; 2016; 17(5):2605-10. PubMed ID: 27268638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of serum-free light-chain levels with markers of renal function.
    Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
    Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of serum free light chain in patients with multiple myeloma].
    Zhang SS; Wu S; Qu XY; Xu J; Liu P; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):930-5. PubMed ID: 23998588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation.
    Alejandre ME; Pavlovsky MA; Remaggi G; Corrado C; Fernandez I; Milone G; Pavlovsky A; Madalena L; Pandolfo M; Facio ML; Bresciani P; Pavlovsky S; Pizzolato MA
    Clin Chem Lab Med; 2012 Apr; 50(6):1093-7. PubMed ID: 22706252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
    Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum free light chains in clinical laboratory diagnostics.
    Jenner E
    Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof].
    Sui WW; Yao HJ; Wang YF; Wang L; Zhang K; Xu Y; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3158-60. PubMed ID: 18269880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
    Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD
    Cancer; 2015 Mar; 121(6):853-62. PubMed ID: 25377852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Test of Serum Free Light Chain and Its Clinical Significance in Light Chain Multiple Myeloma].
    Song P; An ZM; Zhou XG; Li F; Wang LP; Zhao Q; Yu YP; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1357-61. PubMed ID: 26524037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
    Tacchetti P; Rocchi S; Zamagni E; Barbato S; Rizzello I; De Cicco G; Pantani L; Mancuso K; Fusco A; Dozza L; Ursi M; Favero E; Terragna C; Testoni N; Cavo M
    Am J Hematol; 2022 Dec; 97(12):1607-1615. PubMed ID: 36198076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
    Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
    PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma.
    Han X; Wang J; Zhang N; Yao J; Feng Y; Li D; Liu P; Yang J; Zhou S; Qin Y; Yang S; Gui L; He X; Shi Y
    Leuk Res; 2014 Nov; 38(11):1291-8. PubMed ID: 25287608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma.
    Uljon SN; Richardson PG; Schur PH; Anderson KC; Tanasijevic MJ; Lindeman NI
    Clin Chim Acta; 2011 Mar; 412(7-8):562-8. PubMed ID: 21144845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.